Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib

Blood

Volumn 123, Issue 26, 2014, Pages 4132-4135

  Wodarz, Dominik ^a   Garg, Naveen ^b   Komarova, Natalia L ^a   Benjamini, Ohad ^b   Keating, Michael J ^b   Wierda, William G ^b   Kantarjian, Hagop ^b   James, Danelle ^c   O'Brien, Susan ^b   Burger, Jan A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c PHARMACYCLICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IBRUTINIB;

ADULT; AGED; ARTICLE; BLOOD; CELL KINETICS; CELLULAR DISTRIBUTION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; FEMALE; HUMAN; LEUKEMIA CELL; LYMPH NODE; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; SPLEEN SIZE; TISSUES;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASTIC CELLS, CIRCULATING; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES;

EID: 84903650423     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-02-554220     Document Type: Article

References (15)

1. Burger JA, Chiorazzi N. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol. 2013;34(12):592-601.
2. Burger JA, Buggy JJ. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765). Leuk Lymphoma. 2013;54(11):2385-2391.
3. Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/ refractory B-cell malignancies. J Clin Oncol. 2013; 31(1):88-94.
4. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32-42.
5. Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507-516.
6. Woyach JA, Smucker K, Smith LL, et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood. 2014;123(12): 1810-1817.
7. Messmer BT, Messmer D, Allen SL, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest. 2005;115(3):755-764. (Pubitemid 40322252)
8. Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117(23):6287- 6296.
9. Ponader S, Chen SS, Buggy JJ, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012; 119(5):1182-1189.
10. de Rooij MF, Kuil A, Geest CR, et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood. 2012;119(11):2590-2594.
11. Burger JA, Montserrat E. Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling. Blood. 2013;121(9): 1501-1509.
12. Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010;115(13): 2578-2585.
13. Hoellenriegel J, Meadows SA, Sivina M, et al. The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011;118(13): 3603-3612.
14. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014; 370(11):997-1007.
15. Shaw RK, Boggs DR, Silberman HR, Frei E. A study of prednisone therapy in chronic lymphocytic leukemia. Blood. 1961;17(2): 182-195.